Previous 10 | Next 10 |
INmune Bio ( NASDAQ: INMB ) said on Monday that Health Canada had issued a no objection letter to begin trial of XPro1595 to treat mild Alzheimer’s Disease in Canada. "We are pleased that Canada is now part of this international Phase II trial,...
BOCA RATON, FL., Nov. 14, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces...
INmune Bio, Inc. (INMB) Q3 2022 Results Conference Call November 02, 2022 04:30 PM ET Company Participants David Moss - Chief Financial Officer Dr. RJ Tesi - Chief Executive Officer Dr. CJ Barnum - Head of Neuroscience Dr. Mark Lowdell - Chief Scientific Offi...
INmune Bio press release ( NASDAQ: INMB ): Q3 GAAP EPS of -$0.43. As of September 30, 2022, the Company had cash and cash equivalents of approximately $57.4 million. For further details see: INmune Bio GAAP EPS of -$0.43
BOCA RATON, Fla., Nov. 02, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today reported its fin...
Management to host conference call and webcast at 4:30 pm E T on that day Boca Raton, Florida, Oct. 26, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments tha...
Dr. Mark Lowdell, CSO, Presented Latest Data in First Plenary Session at The Innate Killer Summit Europe, London Today BOCA RATON, Fla, Oct. 19, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology compan...
Summary Alzheimer's Disease is one of the largest unmet medical needs. Today, there are 139 drugs in clinical trials for Alzheimer's. In this piece, we dive into 8 of the most impactful and promising trials. Introduction Alzheimer's disease is the largest unmet...
Summary E. Roudasev is a senior business manager for a major financial institution. Her areas of interest are biotech, environmental tech and credit risks. The opportunities in under the radar biotechs, typical sources of mispricings, and how to manage risk are topics discussed. ...
Boca Raton, FL, Sept. 07, 2022 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical- stage immunology company focused on developing treatments that harness the patient’s immune system to fight disease, announced today that RJ Tesi, M.D., Chief Executive Officer will present ...
News, Short Squeeze, Breakout and More Instantly...
The planned interim analysis confirms the accuracy of the sample size calculations and statistical power for EMACC, the primary endpoint. The interim analysis, performed by a third-party, demonstrated no need to change trial design or size. BOCA RATON, Fla., June 27, 2024 (GLOBE N...
2024-06-12 14:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Boca Raton, Florida, May 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, is set to join the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Indexes annual r...